ALIPAY+
13.1.2023 10:33:43 CET | Business Wire | Press release
Alipay+, a provider of global cross-border digital payment and marketing solutions announced today that, through Alipay+, Macao merchants are offering lucrative incentives inside AlipayHK – one of the most popular e-wallets in Hong Kong – to attract travelers and boost local consumption as inter-city travels are expected to soon recovered to pre-pandemic levels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230113005107/en/
From January 20, users of AlipayHK will be able to find featured Macao shops and their special offers for tourists such as digital coupons inside the app’s Alipay+ Rewards section. (Photo: Business Wire)
From January 20, users of AlipayHK will be able to find featured Macao shops and their special offers for tourists such as digital coupons inside the app’s Alipay+ Rewards section – a joint effort of several parties including Macao’s Economic and Technological Development Bureau, five local chambers of commerce, Macau Pass, Ant Group and over a hundred small and medium-sized merchants in Macao.
The latest campaign inside AlipayHK’s Alipay+ Rewards section was established to boost local consumption as more and more tourists return to the city. AlipayHK, which owns most active users in Hong Kong, has been accepted at nearly 90% merchants in Macao.
“Powered by Alipay+, this online campaign on AlipayHK, which has 3.3 million active users, will help promote local Macao merchants and increase their exposures, as well as position Macao as an attractive tourist destination for travelers from Hong Kong in the short- to longer-term,” said Ng Wah Wai, Director of the Industry and Commerce Association of Macau. He added that the campaign is also expected to connect Macao merchants with more tourists from other overseas markets through Alipay+ in the future.
“With the joint efforts from all parties, we hope this campaign on AlipayHK could further explore the potential of Macao’s featured merchants via online promotion, enhance the attractiveness of Macao’s tourism consumption, encourage the second and third-time visits of tourists to Macao, and jointly create new momentum for Macao’s overall economic growth,” said Ng.
On January 8, China announced first steps to optimize regulations on travel between the mainland and Hong Kong, lifting quarantine requirements that were in place for almost three years. A surge in number of travelers between the two cities is expected in response to the relaxation of travel restrictions.
Venetia Lee, General Manager of Ant Group Greater China International Business, said: “We are pleased to work with the Macao government and five local chambers of commerce to attract more Hong Kong tourists to Macao and stimulate local tourism consumption, in recognition of AlipayHK as a valuable partner.”
“AlipayHK is dedicated to playing a greater role in the realization of connectivity in the Great Bay Area through Alipay+ payment and marketing solutions, and we will continue to work with different ecological partners in the future to provide more convenient and valuable services to our users,” she added.
Alipay+’s Expanding Global Footprint
Developed by Ant Group, Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing offers by merchants through Alipay+.
Alipay+ Rewards is a new digital marketing platform developed by Alipay+ and partner e-wallets to help global brands better engage with consumers worldwide by offering incentives and exclusive services.
Currently, Alipay+ has over 15 mobile payment partners globally, including AlipayHK, that have covered more than 1 billion digital-savvy consumers. South Korea’s Kakao Pay, another e-wallet partners of Alipay+, has also been accepted at local merchants in Macao.
Globally, over the past year, Alipay+’s merchant coverage has more than doubled since last year to over 2.5 million, which includes regional and global digital entertainment providers, lifestyle services, e-commerce platforms and a wide range of brick-and-mortar businesses that cover major airports, shopping centers, duty free shops, convenience stores, cafes, restaurants and tourism facilities.
Businesses across Japan, South Korea, Singapore, Malaysia and other Southeast Asian markets are embracing Alipay+ to connect with global digital payment methods through one-time integration, and better engage with over 1 billion consumers.
Alipay+’s merchant coverage includes over 1,000 online platforms, more than 10 major airports, over 90,000 convenience stores, over 360,000 restaurants, nearly 200,000 taxis and major hotel brands, department stores, duty-free shops and tourist facilities in Asia and Europe.
About Alipay+
Alipay+ offers unified global mobile payment and marketing solutions that connect merchants with multiple e-wallets and payment methods from different countries and regions by collaborating with global partners. Consumers can conveniently use their preferred local payment methods while transacting seamlessly in a different market and be able to enjoy marketing offers by the merchants through Alipay+. Alipay+ is developed by Ant Group, the owner and operator of Alipay, one of the world’s leading digital open platforms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230113005107/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
